"Treatment"

A new clinical trial update shows that oxitinib (known as Teresa, or 9291) nearly doubled disease-free survival and halved post-operative recurrence rates in lung cancer patients carrying an early stage EGFR mutation!

Prostate cancer, which has been increasing in incidence worldwide in recent years, is now a more common cancer among Japanese men. Often, patients with prostate cancer have a poor prognosis and poor survival once they have developed multiple recurrent metastases after treatment with hormones and are difficult to treat with conventional radiotherapy.

Every disease has a cause, and we are all sick because of various factors. Understanding the causes of diseases can help us to prevent them, which will help our health a lot.

With more and more new cutting-edge drugs emerging, the standard treatment paradigm for breast cancer is now rapidly changing, and the future is looking brighter for patients.

Leukaemia is a very complex disease that causes fever and infection and bleeding, so it needs to be treated early so that it can be gradually controlled and the patient's symptoms can be gradually relieved

Almost everyone hopes to have a young and healthy heart. However, 62% of people over 40 years old have cardiovascular disease or risk factors to varying degrees, and 80% of them have not yet fully understood how to maintain a healthy heart. Medical research shows that among all internal organs, the heart is most likely to suffer from "obesity", especially in patients with hypertension, which can also lead to gradual thickening of the heart muscle.

For many patients after early lung cancer surgery, it is common for them to worry about recurrence. For this reason, many patients tend to undergo CT examinations more closely to ensure that they have not had a recurrence. However, a recent new study conducted by researchers from Washington University School of Medicine in St. Louis found that even with more frequent CT reviews, post-operative outcomes for lung cancer did not improve...

Data from a trial show that adding the new drug Eganelisib to standard treatment significantly improves the length of survival for patients with triple-negative breast cancer whose disease remains unexacerbated. Patients benefited regardless of their PD-L1 status.

The trial is testing the effectiveness of two chemotherapy drugs, oxaliplatin and gemcitabine, in combination with radiotherapy, an approach that has been used to treat other aggressive tumours

The US FDA has approved pablizumab (Keytruda) as an adjuvant treatment for early-stage non-small cell lung cancer. In the trial, pablizumab (Keytruda) significantly prolonged cancer-free survival in patients compared to placebo.